- Home
- ETJ vs CTNM Comparison
ETJ vs CTNM Comparison
Compare ETJ & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | ETJ | CTNM |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 566.0M | 507.0M |
| IPO Year | 2007 | 2024 |
Fundamental Metrics
Financial Performance| Metric | ETJ | CTNM |
|---|---|---|
| Price | $8.17 | $12.23 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 175.8K | ★ 322.2K |
| Earning Date | 01-01-0001 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.70 | $3.35 |
| 52 Week High | $9.12 | $16.33 |
Technical Indicators
Market Signals| Indicator | ETJ | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 32.40 | 45.61 |
| Support Level | N/A | $10.17 |
| Resistance Level | $9.01 | $13.18 |
| Average True Range (ATR) | 0.11 | 1.07 |
| MACD | -0.03 | -0.15 |
| Stochastic Oscillator | 27.87 | 36.92 |
Price Performance
Historical ComparisonAbout ETJ Eaton Vance Risk-Managed Diversified Equity Income Fund of Beneficial Interest
Eaton Vance Risk-Managed Diversified Equity Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income and gains, with a secondary objective of capital appreciation. The group invests in various sectors such as financials, healthcare, consumer discretionary, consumer staples, industrials, energy, utilities, telecommunication services, and materials. Under normal market conditions, the Fund's investment program consists of majorly owning a diversified portfolio of common stocks and employing a variety of options strategies.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.